ArticlePharmaceuticals (Basel, Switzerland)2021

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer.

Silvia Martini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.